Sunday 27th July, 05:40 AM JST TOKYO — A sense of crisis is growing among the Japanese pharmaceutical industry in the face of closings of laboratories of foreign drugmakers and China’s emphasis on the biomedical industry as a national strategy. Bayer AG shut down its Kobe research center and GlaxoSmithKline closed its lab in Tsukuba, Ibaraki Prefecture, last year. The Kobe research center prided itself on technical skills that led the company to successfully produce induced pluripotent stem (iPS) cells from human skin. Novartis Pharma KK reportedly plans to shut its research office in Tsukuba within this year. Since the start of the 21st century, China has successfully lured foreign pharmaceutical companies, including the Roche group, Astrazeneca Co, Novartis Pharma and GSK, to Shanghai thanks to its campaign to allocate...
[read full story]
Your Web Site
